Aclasta licence extended to include use in men

The licence for Aclasta (zoledronate) has been extended to include the treatment of osteoporosis in men at increased risk of fracture, including those with a recent low-trauma hip fracture.

The recommended dose for the treatment of postmenopausal osteoporosis and osteoporosis in men is a single 5mg intravenous infusion administered once a year.

View Aclasta drug record

Further information: Novartis

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

NSAIDs safe in COVID-19, study confirms

NSAIDs safe in COVID-19, study confirms

Concerns were raised early in the COVID-19 pandemic...

Deleted products - live tracker

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

New and deleted indications - live tracker

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...